NEW YORK--(BUSINESS WIRE)--Pfizer Inc. announced today the discontinuation of A4021018 (also known as ADVIGO 1018), a Phase 3 trial examining the effects of investigational compound figitumumab (CP-751,871) in combination with erlotinib as a second/third-line treatment in patients with previously treated advanced non-adenocarcinoma non-small cell lung cancer […]

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. announced today that two Phase 3 studies of Sutent® (sunitinib malate) in advanced breast cancer did not meet their primary endpoints. The SUN 1064 Phase 3 study of sunitinib in combination with docetaxel for the first-line treatment of patients with advanced HER-2 negative breast cancer did not show a statistically sig […]

PRINCETON, N.J. & NEW YORK--(BUSINESS WIRE)--Apixaban, an oral anticoagulant being developed by Bristol-Myers Squibb Company (NYSE: BMY) and Pfizer Inc. (NYSE: PFE), was statistically superior to 40 mg once daily enoxaparin in reducing the incidence of venous thromboembolism in patients undergoing elective total knee replacement surgery, according to the […]

NEW YORK--(BUSINESS WIRE)--Amgen and Pfizer have once again partnered with Tim Gunn, television host, fashion consultant and chief creative officer of Liz Claiborne, Inc., to launch the second year of Addressing Psoriasis™, the disease awareness program designed to help people with psoriasis get more information about their condition and feel more confident […]

NEW YORK & SAN FRANCISCO--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) and Medivation, Inc. (NASDAQ: MDVN) today announced results from two Phase 3 trials of the investigational drug dimebon (latrepirdine*) in patients with Alzheimer’s disease (AD). In the CONNECTION trial, dimebon did not meet its co-primary or secondary efficacy endpoints compared to place […]

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. invites investors and the general public to view and listen to a webcast of a discussion with members of Pfizer’s leadership team at an investor breakfast at the Cowen and Company 30th Annual Healthcare Conference on Tuesday, March 9, 2010 at 7:00 a.m. Eastern Standard Time. To view and listen to the webcast, visit our […]

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. today announced that William Ringo will retire from the company. Mr. Ringo made many important contributions to advance the company’s innovative business development activities. “Bill has accomplished a great deal in positioning Pfizer for future success,” said Jeff Kindler, chairman and chief executive officer, Pfizer. […]

NEW YORK--(BUSINESS WIRE)--Pfizer Inc (NYSE:PFE) announced today that the United States Centers for Disease Control and Prevention's (CDC’s) Advisory Committee on Immunization Practices (ACIP) has recommended the use of Prevnar 13™ (Pneumococcal 13-valent Conjugate Vaccine [Diphtheria CRM197 Protein]) for healthy children aged 2 months through 59 months […]

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE:PFE) announced today that the United States Food and Drug Administration (FDA) has granted approval for Prevnar 13™ (Pneumococcal 13-valent Conjugate Vaccine [Diphtheria CRM197 Protein]), the Company’s 13-valent pneumococcal conjugate vaccine. Prevnar 13 is indicated for active immunization of children 6 weeks thr […]

INDIANAPOLIS, WHITEHOUSE STATION, N.J. & NEW YORK--(BUSINESS WIRE)--Eli Lilly and Company, Merck (also known as Merck Sharp & Dohme (MSD) outside the USA and Canada), and Pfizer Inc. today announced the formation of the Asian Cancer Research Group, Inc., (ACRG), an independent, not-for-profit company established to accelerate research and ultimately […]